Früher|Nächster

Mechanism of Naoxintong Capsules Against Ischemia-reperfusion Injury in Rats via Inhibiting Pericyte Contraction Based on RHOA/ROCK1 Pathway

  • role： First author第一作者
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

  • Email：wenyinlian11@bucm.edu.cn
  • Introduction：文胤琏，在读硕士，从事脑缺血机制及中药干预研究，E-mail：wenyinlian11@bucm.edu.cn
WEN Yinlian,  
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

SHANG Jinfeng,  
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

WANG Bohong,  
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

WEI Wanting,  
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

ZHANG Xiaolu,  
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

HUANG Guijinfeng,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Chinese Materia Medica， Beijing University of Chinese Medicine， Beijing 102488， China

  • Email：liuxin1011@bucm.edu.cn
  • Introduction：刘欣，博士，教授，从事脑缺血机制及中药干预研究，E-mail：liuxin1011@bucm.edu.cn
LIU Xin*

Resümee

Das Ziel der Studie war es, die Mechanismen der Wirkung von Gehirnkapseln bei der Hemmung der perivaskulären Zellkontraktion, die durch den RHOA/ROCK1-Weg induziert wird, bei der Hirnischämie-Reperfusionsverletzung bei Ratten zu untersuchen. 90 Ratten wurden zufällig in eine Gruppe mit Placebo-Operation, eine Modellgruppe, eine Ginkgo-Biloba-Extrakt-Gruppe (21,6 mg/kg-1) und Gruppen mit niedriger, mittlerer und hoher Dosierung von Gehirnkapseln (55, 110, 220 mg/kg-1) mit jeweils 15 Ratten eingeteilt. Temporäre Blockierungen der mittleren Hirnarterie (tMCAO) wurden in allen Gruppen mit Ausnahme der Placebo-Operatiosgruppe verwendet. Es wurden die Bewertung der Nervenfunktion und der Laserblutsprühfluss für die zerebrale Blutflussbildgebung, die Chloridaldehyd-Triphenyltetrazoliumtetrachlorid (TTC)-Färbung zur Berechnung der Hirninfarkt-Rate, die Heidenhain-Earle (HE)- und Nissl-Färbung zur Untersuchung der pathologischen Veränderungen, die elektronenmikroskopische Untersuchung zur Beobachtung der Morphologie der perivaskulären Zellen, die Evans Blue-Färbung zur Beobachtung der Blut-Hirn-Schranke, die Messung des Albuminspiegels und des ischämisch modifizierten Albuminspiegels verwendet. Quantitative Echtzeit-Polymerase-Kettenreaktion (qPCR) und Western-Blot-Techniken wurden zur Messung der Expression von mRNA und Proteinen von RHOA, ROCK1, Plättchenabgeleitetem Wachstumsfaktorrezeptor β (PDGFRB), α-Glatte Muskel { α-SMA), Striate-Binding-Protein-1 (ZO-1), Matrixmetallopeptadase-2 (MMP-2) und Matrixmetallkurpelenase-9 (MMP-9) verwendet. Im Vergleich zur Placebogruppe zeigten die Ratten der Modellgruppe eine Verminderung der Nervenfunktionsbewertung, einen prozentualen Rückgang des zerebralen Blutflusses, eine Zunahme der Hirninfarktrate (P<0,01), kortikale Neuronenkernverdichtung und Schwellung, eine Verminderung der Anzahl der Nissl-Zellen und des perivaskulären Bereichs, ein Anstieg des Albumingehalts in der Rinde (P<0,05), eine Zunahme der ischämisch modifizierten Albuminspiegel (P<0,01), eine relative Zunahme der mRNA- und Protein Α -SMA, MMP-2 und MMP-9 (P<0,01) und eine verringerte ZO-1-Niveauerhöhung. Im Vergleich zur Model

Schlüsselwort

Naoxintong capsules;ischemia-reperfusion （I/R） injury;pericyte contraction;Ras homolog family member A （RHOA）/Rho-associated coiled-coil containing protein kinase 1 （ROCK1） pathway;pharmacological mechanism

References

  1. 1.
    Report on Stroke Prevention and Treatment in China Writing Group.Brief report on stroke prevention and treatment in China，2021［J］.Chin J Cerebrovasc Dis，2023，20（11）：783-793.
  2. 2.
    LIM S，KIM T J，KIM Y J，et al.Senolytic therapy for cerebral ischemia-reperfusion injury［J］.Int J Mol Sci，2021，22 （21）：11967.
  3. 3.
    WOLLENWEBER F A，TIEDT S，ALEGIANI A，et al. Functional outcome following stroke thrombectomy in clinical practice［J］.Stroke，2019，50 （9）：2500-2506.
  4. 4.
    JIA M，JIN F，LI S，et al. No-reflow after stroke reperfusion therapy：An emerging phenomenon to be explored［J］.Cns Neurosci Ther，2024，30 （2）：e14631.
  5. 5.
    YUAN L，ZHANG X，WU J N，et al.Research progress of no-reflow phenomenon after revascularization in acute ischemic stroke［J］.Chin J Clin Neurosci，2023，36（6）：466-470.
  6. 6.
    SIMS D E. Diversity within pericytes［J］.Clin Exp Pharmacol Physiol，2000，27 （10）：842-846.
  7. 7.
    ZHANG Y，JIANG M，GAO Y，et al."No-reflow" phenomenon in acute ischemic stroke［J］.J Cereb Blood Flow Metab，2024，44（1）：19-37.
  8. 8.
    GARCÍA-QUINTANS N，SÁNCHEZ-RAMOS C，PRIETO I，et al. Oxidative stress induces loss of pericyte coverage and vascular instability in PGC-1Α-deficient mice［J］.Angiogenesis，2016，19 （2）：217-228.
  9. 9.
    SHI T F，ZHOU Z，JIANG W J，et al.Hyperglycemia-induced oxidative stress exacerbates mitochondrial apoptosis damage to cochlear stria vascularis pericytes via the ROS-mediated Bcl-2/CytC/AIF pathway［J］.Redox Rep，2024，29 （1）：2382943.
  10. 10.
    DURHAM J T，SURKS H K，DULMOVITS B M，et al. Pericyte contractility controls endothelial cell cycle progression and sprouting：Insights into angiogenic switch mechanics［J］.Am J Physiol Cell Physiol，2014，307 （9）：C878-C892.
  11. 11.
    LI T S， YANG J， YANG C H. Pathogenesis of coronary NRP and TCM strategy in syndrome differentiation and treatment based on "collateral disease theory"［J］.Acta Chin Med Pharmacol，2022，50（12）：82-85.
  12. 12.
    XU J C，QIN Q J，SUN W M， et al.Exploration on dredging collateralsin traditional Chinese medicine and brain microcirculation dysfunction after cerebral infarction［J］. Liaoning J Tradit Chin Med，2021，48（1）：78-80.
  13. 13.
    HUANG P J，HE A D，CHEN H Y.Curative effect of Naoxintong capsuless combined with metoprolol on arrhythmia of coronary heart disease and its effect on inflammatory factors［J］.J New Chin Med，2023，55（21）：24-28.
  14. 14.
    LIU X，WANG Q，CUI Y，et al.Multiple protein and mRNA expression correlations in the rat cerebral cortex after ischemic injury and repair due to Buchang Naoxintong Jiaonang （BNJ） intervention［J］.Biomed Pharmacother，2020，doi：.
  15. 15.
    LONGA E Z，WEINSTEIN P R，CARLSON S，et al. Reversible middle cerebral artery occlusion without craniectomy in rats［J］.Stroke，1989，20（1）：84-91.
  16. 16.
    WANG Z，DU X，YU D，et al. Sufentanil alleviates cerebral ischemia-reperfusion injury by inhibiting inflammation and protecting the blood-brain barrier in rats［J］.Eur J Histochem，2022，66（1）：3328.
  17. 17.
    DENG K，COLLABORATORS G C O D.Global Burden of 288 Causes of Death And Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations， 1990-2021：A systematic analysis for the global burden of disease study 2021［J］.Lancet，2024，403 （10440）：2100-2132.
  18. 18.
    RANDOLPH S A.Ischemic stroke［J］.Workplace Health Saf，2016，64（9）：444.
  19. 19.
    DANG C，LU J，SONG H Q，et al.Chinese expert consensus on clinical evaluation and treatment of ischemic penumbra in acute cerebral infarction［J］.Chin J Nerv Ment Dis，2021，47（6）：324-335.
  20. 20.
    HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke［J］.N Engl J Med，2008，359（13）：1317-1329.
  21. 21.
    KLONER R A， KING K S， HARRINGTON M G. No-reflow phenomenon in the heart and brain［J］.Am J Physiol Heart Circ Physiol，2018，315（3）：H550-H562.
  22. 22.
    ZHANG S S，WANG J L.Discussion on syndrome differentiation and treatment of stroke from the perspective of latent toxin damaging defense， Qi，nutrient， and blood phases［J］.Global Tradit Chin Med，2023，16（2）：270-275.
  23. 23.
    LIU S， ZHANG Z X， KONG L B， et al. A principle-method-prescription-medicine system for no reflow after vascular recanalization in ischemic stroke based on the theory of vessels and collaterals in traditional Chinese medicine［J］. World Chin Med，2023，18（13）：1834-1838.
  24. 24.
    LEI Y X， CHANG M L， WANG H H， et al. Naoxintong capsuless treat cardiac injury after cerebral ischemia via TLR2/TLR4 signaling pathway［J］. Chin J Exp Tradit Med Form，2023，29（24）：104-112.
  25. 25.
    FAN S N. Intervention and mechanism of Qingkailing on pericytes morphology and function after cerebral infarction ［D］.Beijing：Beijing University of Chinese Medicine，2020.
  26. 26.
    METHNER C，MISHRA A，GOLGOTIU K，et al. Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis［J］.Am J Physiol Heart Circ Physiol，2019，317 （2）：H255-H263.
  27. 27.
    YEMISCI M，GURSOY-OZDEMIR Y，VURAL A，et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery［J］.Nat Med，2009，15 （9）：1031-1037.
  28. 28.
    KORTE N，ILKAN Z，PEARSON C L，et al.The Ca2+-gated channel tmem16a amplifies capillary pericyte contraction and reduces cerebral blood flow after ischemia［J］.J Clin Invest，2022，132 （9）：e154118.
  29. 29.
    LEE C H，AHN J H，LEE T K，et al. Comparison of neuronal death， blood-brain barrier leakage and inflammatory cytokine expression in the hippocampal CA1 region following mild and severe transient forebrain ischemia in gerbils［J］.Neurochem Res，2021，46 （11）：2852-2866.
  30. 30.
    LIDONG D，ZHANGHONG X，HUAWU M，et al. Ischemia modified albumin and miR-126 play important role in diagnosis of posterior circulation transient ischemic attack and prediction of secondary cerebral infarction［J］.Neurol India，2021，69 （1）：75-80.
  31. 31.
    STRATMAN A N，SCHWINDT A E，MALOTTE K M，et al. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization［J］.Blood，2010，116 （22）：4720-4730.
  32. 32.
    GENOVÉ G，MOLLICK T，JOHANSSON K. Photoreceptor degeneration，structural remodeling and glial activation：A morphological study on a genetic mouse model for pericyte deficiency［J］.Neuroscience，2014，279：269-284.
  33. 33.
    MACHIDA T，TAKATA F，MATSUMOTO J，et al. Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting the blood-brain barrier in vitro［J］.Neurosci Lett，2015，599：109-114.
  34. 34.
    TAKAHASHI Y，MAKI T，LIANG A C，et al. p38 MAPKinase mediates transforming-growth factor-β1-induced upregulation of matrix metalloproteinase-9 but not -2 in human brain pericytes［J］.Brain Res，2014，1593：1-8.
  35. 35.
    TAKATA F，DOHGU S，MATSUMOTO J，et al.Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α， releasing matrix metalloproteinase-9 and migrating in vitro［J］.J Neuroinflammation，2011，8：106.
  36. 36.
    SLADOJEVIC N，YU B，LIAO J K. ROCK as a therapeutic target for ischemic stroke［J］.Expert Rev Neurother，2017，17 （12）：1167-1177.
  37. 37.
    LU W，CHEN Z，WEN J.RhoA/ROCK signaling pathway and astrocytes in ischemic stroke［J］.Metab Brain Dis，2021，36 （6）：1101-1108.
  38. 38.
    ZHANG Y，MIAO L，PENG Q，et al.Parthenolide modulates cerebral ischemia-induced microglial polarization and alleviates neuroinflammatory injury via the Rhoa/Rock pathway［J］.Phytomedicine，2022，105：154373.
  39. 39.
    RIKITAKE Y，KIM H H，HUANG Z，et al.Inhibition of Rho kinase （Rock） leads to increased cerebral blood flow and stroke protection［J］.Stroke，2005，36 （10）：2251-2257.
  40. 40.
    ALARCON-MARTINEZ L，YILMAZ-OZCAN S，YEMISCI M，et al.Retinal ischemia induces α-SMA-mediated capillary pericyte contraction coincident with perivascular glycogen depletion［J］.Acta Neuropathol Commun，2019，7 （1）：134.
  41. 41.
    O'FARRELL F M，ATTWELL D.A role for pericytes in coronary no-reflow［J］.Nat Rev Cardiol，2014，11（7）：427-432.
  42. 42.
    KOROL A，TAIYAB A，WEST-MAYS J A.RHOA/ROCK signaling regulates TGFB-induced epithelial-mesenchymal transition of lens epithelial cells through Mrtf-A［J］.Mol Med，2016，22：713-723.

Lesen Sie die ganze Passage

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website